Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
News
+ Font Resize -

Glooko enters global partnership with insulin dosing algorithm company, Hedia

Palo Alto, California
Wednesday, April 12, 2023, 12:00 Hrs  [IST]

Glooko, Inc., announced a new Global partnership with Hedia, integrating its technology into Glooko’s diabetes management platforms for healthcare providers and people with diabetes. The collaboration will provide an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutic technologies to enhance access for people with type 1 and type 2 diabetes requiring bolus insulin dosing advice.

With the Glooko platforms, patients currently have the ability to share their diabetes data with their healthcare providers (HCPs), including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice, which will provide personalized care and reduce the burden of manually calculating required insulin doses. In addition, when used in conjunction with connected insulin pens, the integrated solution facilitates a high level of visibility for HCPs who are managing patients on multiple daily injection (MDI) therapy. This integration enhances the capabilities of Glooko’s remote patient monitoring (RPM) and supports virtual consultations for MDI patients.

“We are very pleased to partner with Hedia to offer this algorithm-driven innovation for personalized healthcare for diabetes patients and their healthcare teams,” stated Russ Johannesson, CEO of Glooko. “The robust clinical data supporting Hedia’s efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps. This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels.”

Peter Lucas, CEO of Hedia said, “We are thrilled to call Glooko, a company with such an extensive clinical network, our partner in digital health. In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance and cybersecurity. Glooko has demonstrated their strength in these areas with multiple third-party certifications and that’s a key driver behind our partnership. Hedia’s Class IIb medical device designation ensures that the best solutions are being provided to patients and their care teams.”

The initial European launch of the integration is expected in the fourth quarter of 2023 and first quarter of 2024.

Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platforms.

Hedia is a leading digital therapeutics company within diabetes, committed to help people with insulin-dependent diabetes gain control of their condition.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
Avians_2025
Asia_Lab_Expo2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram